- Healthcare 150
- Posts
- Healthcare Cybersecurity Is Booming — Don’t Get Left Behind
Healthcare Cybersecurity Is Booming — Don’t Get Left Behind
The healthcare cybersecurity market is set to nearly quadruple to $126B by 2034. Investors, providers, and tech players who move now will define the next decade of digital trust.
In partnership with
Good morning, ! This week we’re diving into the sustained growth of the Healthcare Cybersecurity Market; Cardiovascular MedTech registers a 6.5% CAGR trend reshaping Healthtech; AI makes healthcare more human, not robotic.
Want to advertise in Healthcare 150? Check out our self-serve ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
DATA DIVE
Healthcare’s $126B Firewall
The healthcare cybersecurity market is no longer a side hustle—it’s a mega-industry. Valued at $27.26B in 2024, it’s projected to nearly quadruple to $126.70B by 2034. That’s a 16.6% CAGR, fueled by everything from ransomware attacks to regulators with clipboards.
North America still leads with 41% of the pie, but Asia-Pacific is the growth rocket, nearing 20% CAGR thanks to digital hospitals and smart-device rollouts. Cloud Security dominates at 37% of spend, while Digital Identity isn’t far behind at 27%.
The takeaway: In healthcare, protecting data is now as valuable as protecting patients—and investors are betting accordingly.
TREND OF THE WEEK
AI’s Bedside Manner Upgrade
AI in healthcare isn’t the cold robot patients once feared—it’s becoming the doctor’s assistant that actually makes care more human. 45% of patients say the biggest upside is better health outcomes, while 43% point to fewer mistakes and faster access to doctors. Perhaps most telling, 39% want AI to free up clinicians’ time for more personal interactions. Translation: patients will trust AI only if it augments care, not automates compassion. The winners in this shift will be companies deploying AI to cut admin drag, reduce error rates, and give providers back the one thing technology rarely delivers: time. (More)
Exclusive Offer For 150 Media Readers:
📍 October 15, 2025 | Well& by Durst, NYC
Get 25% OFF and join 300+ private markets leaders—GPs, LPs, operating partners, and advisors—for a single day of insights, strategy, and dealmaking at the New York Private Capital Summit.
This isn’t another networking event. It’s where strategy meets substance:
→ Keynotes from HarbourVest’s CEO, WSJ, Bloomberg, Australian Super
→ Deep-dives on secondaries, direct lending, GenAI, and ESG
→ Practical panels on fund formation, human capital, and tax strategy
→ A spotlight on emerging liquidity tools and NAV-based financing
With over 50 senior speakers from firms like Apollo, KKR, Carlyle, Neuberger Berman, and Warburg Pincus, the Summit is designed for decision-makers driving the next decade of private capital.
HEALTHTECH CORNER
Medtech’s MVPs: Cardiovascular Technologists
The unsung heroes of the heart game? Cardiovascular technologists. As cardiovascular disease tightens its grip on Americans—from boomers to toddlers—the demand for techs who wield EKGs and ultrasounds is climbing faster than your pulse during a Peloton class. Behind this spike: an aging population, underdiagnosed women’s heart health, and even childhood cases tied to congenital defects. The Medtech backdrop? A $59B market ballooning to $91.7B by 2030, thanks to AI diagnostics, telehealth, and consolidation plays like J&J’s $16.6B Abiomed buy. Cardiovascular techs—70% women—are now frontline enablers in a system shifting toward value-based care. With workforce shortages looming and hospital margins squeezed, this is one profession that’s saving lives and smoothing EBITDA. (More)
PRESENTED BY INSIGHTSOFTWARE
It's not you, it’s your tax tools
Tax teams are stretched thin and spreadsheets aren’t cutting it. This guide helps you figure out what to look for in tax software that saves time, cuts risk, and keeps you ahead of reporting demands.
DEAL OF THE WEEK
Genmab Bets $8B on a Biotech Jackpot
Genmab is shelling out $8.0B in cash to acquire Dutch biotech Merus at $97/share—a tidy 41% premium. The crown jewel: petosemtamab, a Phase 3 bispecific antibody with not one but two FDA Breakthrough Therapy Designations. Genmab’s play is textbook biotech M&A: buy late-stage innovation, plug it into your oncology commercialization engine, and aim for multi-billion sales by 2029. Financing comes via $5.5B in debt, but Genmab swears it will delever fast (<3x leverage in two years). If petosemtamab hits, Genmab goes from antibody specialist to oncology juggernaut—with four proprietary programs lined up for 2027 launches. (More)
REGIONAL FOCUS
South America’s Medical Tourism Surge
The South American medical tourism market is on a fast climb—from $545M in 2024 to a projected $1.41B by 2035, growing at a 9% CAGR.
While global healthcare costs soar, South America is emerging as a cost-effective destination for elective and complex medical procedures. Countries like Colombia, Brazil, and Costa Rica are investing in international accreditation, infrastructure, and specialized services to attract foreign patients—particularly from North America and Europe.
Why this matters: For investors, this growth reflects a broader shift in cross-border care economics. Health systems and private insurers may increasingly direct patients toward high-quality, lower-cost regional providers. Meanwhile, hospital groups, real estate developers, and MedTech suppliers stand to benefit from the build-out of medical tourism hubs.
South America isn’t just exporting coffee and commodities—it’s quietly becoming a healthcare destination. (More)
TOGETHER WITH MORNING BREW
An espresso shot for your brain
The problem with most business news? It’s too long, too boring, and way too complicated.
Morning Brew fixes all three. In five minutes or less, you’ll catch up on the business, finance, and tech stories that actually matter—written with clarity and just enough humor to keep things interesting.
It’s quick. It’s free. And it’s how over 4 million professionals start their day. Signing up takes less than 15 seconds—and if you’d rather stick with dense, jargon-packed business news, you can always unsubscribe.
"You don't need to be a genius or a visionary or even a college graduate to be successful. You just need a framework and a dream."
Michael Dell